C4 Therapeutics to Present at the Jefferies Virtual London Healthcare Conference
C4 Therapeutics (Nasdaq: CCCC), a biopharmaceutical innovator, will present at the Jefferies Virtual London Healthcare Conference on November 19, 2020, at 8:30 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
C4 Therapeutics (Nasdaq: CCCC), a biopharmaceutical innovator, will present at the Jefferies Virtual London Healthcare Conference on November 19, 2020, at 8:30 a.m. ET. C4T specializes in a unique class of small-molecule drugs aimed at selectively degrading disease-causing proteins, targeting conditions like cancer and neurodegenerative diseases. A live webcast of the presentation will be available on their website, with a replay archived for two weeks. This targeted protein degradation approach offers potential advantages over traditional therapies, including reduced drug resistance and fewer side effects.
Details
News Market Reaction – CCCC
The recorded move for CCCC in the trading session of this news was -2.57%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroys disease-causing proteins through degradation, today announced that the Company will present at the Jefferies Virtual London Healthcare Conference on Thursday, November 19, 2020 at 8:30 a.m. ET.
A live webcast of the presentation can be accessed under “Events & Presentations” in the Investors section of the company’s website at www.c4therapeutics.com. A replay of the webcast will be archived on the C4T website for at least two weeks following the presentation.
About C4 Therapeutics
C4 Therapeutics (C4T) is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. This targeted protein degradation approach offers advantages over traditional therapies, including the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects through greater selectivity. To learn more about C4 Therapeutics, visit www.C4Therapeutics.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.